6 Reasons why Doctors working with Stem Cells are joining the BioRegen IRB
Apply below for the BioRegen IRB, a biologics company in the U.S. with an active IRB for Stem Cells and Exosomes.
🇺🇸 Reviewed by the Institute of Cellular Regenerative Medicine.
1. Become part of the largest growing wellness and longevity industry
The U.S. stem cell market is growing from $6.75B to $19.54B by 2034. At the same time, an estimated 2,750 unapproved clinics are operating across the country, and the FDA's enforcement authority was confirmed by the Supreme Court in October 2025.
Demand has never been higher. Neither has the regulatory risk. Here's why doctors are choosing the BioRegen IRB.
2. Operate under legal protection
When patients sign in under the IRB, they're signing an attorney-drafted consent form that ties the treatment to a board-reviewed clinical study. That's a layer of legal protection most clinics don't have.
Instead of relying on paperwork that may not hold up, you're protected by a real research framework, built by an FDA compliance attorney and approved by a panel of physicians.
3. Access to premium biologics, from an AATB-accredited lab.
As part of the IRB, you get access to biologics manufactured in an AATB-accredited and FDA-registered lab. Every batch is cGMP-qualified, third-party tested, and U.S. sourced, with CoAs and NTAs included on every order.
And because you're sourcing direct from the manufacturer, you also get manufacturer and 48h delivery across the US.
Dr Jordanna Quinn DO - BioRegen IRB
"Bio Regen's clinical support is unmatched. We get one-on-one training and direct access to a CMO with 40-plus years of orthopedic experience. Because we’re part of their IRB study, our protocols are backed by real data, not guesswork.
That combination of high-quality biologics and a tested, ethical framework is the real reason behind our clinic's high success rate."
4. Increase margins without discounts
Most regenerative clinics are stuck in the same conversation, patients ask for a discount, and the doctor either negotiates or loses the case. The IRB flips that dynamic.
When you offer a subsidized study rate, they stop negotiating and start applying. The full value of the protocol stays intact. The patient feels chosen, not discounted.
And every patient who qualifies signs on for weekly progress updates, giving you case study materials, and referrals, turning every case into a marketing engine for the practice.
5. A real doctor network and data-backed protocols.
Most doctors working with biologics learn through trial and error. IRB-enrolled doctors don't have to.
You get direct access to our Chief Medical Advisor (Dr. Bruce Werber) for protocol guidance.
You get a peer network of doctors running the same biologics.
And you get aggregated outcome data from doctors across the IRB so you operate with data-backed protocols.
Dr Bruce Werber
Former President of the American College of Foot and Ankle Surgeons with 35 years of surgical experience.
6. Become an official investigator in the IRB
Doctors who join the BioRegen IRB become official investigators in an IRB-approved clinical study. That's a competitive advantage almost no competitor in the regenerative space has.
Patients can feel that difference. Other doctors can feel that difference. And in a market where the FDA is shutting down the bottom of the pack, being on the research side is the position you want.
3 steps to apply for the BioRegen IRB
Submit the form
Submit your details and a member of our team will reach out within 24 hours.
Submit your applicationQualify
A short conversation with our team to confirm we're the right fit.
Submit your applicationEnroll.
Meet our Chief Medical Officer, complete onboarding, and start enrolling patients in the study.
Submit your applicationFAQs about the IRB
The BioRegen IRB (Institutional Review Board) is an observational clinical research study reviewed and approved by the Institute of Cellular Regenerative Medicine. Doctors who enroll become official investigators in the study, operating under attorney-drafted consent forms and board-reviewed protocols.
No. It's an observational study, which means you decide how to treat your patients. We don't dictate the dose, indication, or protocol, we collect outcome data on the work you're already doing.
No. Doctors in any state can enroll under the IRB.
Patients submit weekly progress updates through our secure, HIPAA-protected patient app, answering questions on pain, mobility, and overall response to treatment. You can view your own patients' data in real time, and we aggregate anonymized outcome data across the entire IRB network, which is shared back with enrolled doctors over the first 3–6 months.
You decide the protocol you want to run. The IRB collects the data on what's working across your patients and across the network so you can make better-informed decisions over time.